You are here

Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer New Haven Clinical Research Unit
New Haven, Connecticut, 06511 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy female subjects of non childbearing potential and/or male subjects who, at the
time of screening, are between the ages of 18 and 55 years, inclusive.

2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

3. Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all pertinent aspects of the study.

4. Subjects who are willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing).

2. Any condition possibly affecting drug absorption (eg, gastrectomy).

3. A positive urine drug screen.

4. History of regular alcohol consumption exceeding 7 drinks/week for females or 14
drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.

5. Smokers must not exceed the equivalent of 5 cigarettes per day.

6. Treatment with an investigational drug within 30 days (or as determined by the local
requirement) or 5 half lives preceding the first dose of investigational product
(whichever is longer).

7. Screening supine blood pressure100 mm Hg (systolic) or 50 mm Hg (diastolic); or 140 mm
Hg (systolic) or 90 mm Hg (diastolic) following at least 5 minutes of supine rest. If
blood pressure (BP) is 40 mm Hg (systolic) or 90 mm Hg (diastolic), the BP should be
repeated two more times and the average of the three BP values should be used to
determine the subject's eligibility.

8. Screening pulse or heart rate (HR) >100 bpm after at least 5 minutes of rest. If the
pulse/HR is >100 bpm, the pulse/HR should be repeated two more times (separated by at
least 2 minutes) and the average of the three pulse/HR values should be used to
determine the subject's eligibility.

9. Screening 12 lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec. If QTc
exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times
and the average of the three QTc or QRS values should be used to determine the
subject's eligibility.

10. Clinically significant abnormality on chest X ray performed at screening or within 3
months of screening date.

11. History of tuberculosis or active or latent or inadequately treated infection,
positive Quantiferon TB test

12. History of hepatitis or HIV, positive testing for human immunodeficiency virus (HIV),
hepatitis B surface antigen (HepBsAg), hepatitis B core antibodies (HepBcAb) or
hepatitis C antibodies (HCVAb).

NCT02485769
Pfizer
Completed
Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now